<DOC>
	<DOC>NCT00152984</DOC>
	<brief_summary>The primary objective of this study is to demonstrate the superiority of tiotropium compared to placebo in the treatment of patients with COPD and a concomitant diagnosis of asthma</brief_summary>
	<brief_title>Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criteria: Diagnosis of COPD and diagnosis of asthma before the age of 30 Current or exsmokers with a cigarette smoking history of at least 10 packyears Treatment with inhaled steroids at least 1 year before study entry FEV1 increase of more than 12% 30 min. after 400 mcg salbutamol or documented reversibility of 12% documented during the past 5 years FEV1 increase of more than 200 mL 30 min. after 400 mcg salbutamol or documented increase of 200 mL after reversibility test within the last 5 years Post bronchodilator FEV1 less than 80% predicted normal (ECCS) at visit 1 Post bronchodilator FEV1 less than 70% of FVC at visit 1 Exclusion criteria: Respiratory infection or exacerbation 6 weeks prior to Visit 1 or during runin period. Significant diseases other than COPD or asthma Myocardial infarction within the last 6 months Unstable or lifethreatening cardiac arrhythmia requiring intervention or change in therapy in the last year Hospitalisation for heart failure (NYHA Class III or IV) within the last year History of lifethreatening pulmonary obstruction, cystic fibrosis or clinically evident bronchiectasis Known active tuberculosis History of thoracotomy with pulmonary resection History of cancer within the last 5 years (excluding treated basal cell carcinoma) Patients requiring oxygen therapy for more than 1 hour per day Patients currently in a pulmonary rehabilitation programme or who have completed such a programme within 4 weeks before Visit 1 Known hypersensitivity to anticholinergic drugs or lactose</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>